Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation
…, JD Lambris, A Skerra, M Anliker… - Blood, The Journal …, 2017 - ashpublications.org
Eculizumab inhibits the terminal, lytic pathway of complement by blocking the activation of
the complement protein C5 and shows remarkable clinical benefits in certain complement-…
the complement protein C5 and shows remarkable clinical benefits in certain complement-…
[HTML][HTML] Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus …
Objectives Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections
cause coronavirus disease 2019 (COVID-19) and induce a specific antibody response. …
cause coronavirus disease 2019 (COVID-19) and induce a specific antibody response. …
[HTML][HTML] Testosterone deficiency is a risk factor for severe COVID-19
…, S Kaser, GM Pinggera, M Anliker… - Frontiers in …, 2021 - frontiersin.org
Background Male sex is related to increased COVID-19 severity and fatality although
confirmed infections are similarly distributed between men and women. The aim of this …
confirmed infections are similarly distributed between men and women. The aim of this …
[HTML][HTML] Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation
…, N Inoue, T Hirata, S Murata, M Anliker… - The Journal of …, 2019 - Am Soc Clin Investig
Patients with paroxysmal nocturnal hemoglobinuria (PNH) have a clonal population of blood
cells deficient in glycosylphosphatidylinositol-anchored (GPI-anchored) proteins, resulting …
cells deficient in glycosylphosphatidylinositol-anchored (GPI-anchored) proteins, resulting …
Upregulation of checkpoint ligand programmed death-ligand 1 in patients with paroxysmal nocturnal hemoglobinuria explained by proximal complement activation
M Anliker, D Drees, L Loacker, S Hafner… - The Journal of …, 2022 - journals.aai.org
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hemolytic disease driven by impaired
complement regulation. Mutations in genes encoding the enzymes that build the GPI …
complement regulation. Mutations in genes encoding the enzymes that build the GPI …
Comparative analysis of novel complement-targeted inhibitors, MiniFH, and the natural regulators factor H and factor H–like protein 1 reveal functional determinants of …
MJ Harder, M Anliker, B Höchsmann… - The Journal of …, 2016 - journals.aai.org
The serum proteins factor H (FH), consisting of 20 complement control protein modules (CCPs),
and its splice product FH-like protein 1 (FHL-1; consisting of CCPs 1–7) are major …
and its splice product FH-like protein 1 (FHL-1; consisting of CCPs 1–7) are major …
[HTML][HTML] Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay
…, I Tancevski, G Weiss, M Anliker… - Clinical Chemistry and …, 2021 - degruyter.com
Objectives Serological tests detect antibodies against Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) in the ongoing coronavirus disease-19 (COVID-19) pandemic. …
Coronavirus 2 (SARS-CoV-2) in the ongoing coronavirus disease-19 (COVID-19) pandemic. …
[HTML][HTML] Increased PD-L1 surface expression on peripheral blood granulocytes and monocytes after vaccination with SARS-CoV2 mRNA or vector vaccine
…, CQ Schmidt, A Griesmacher, M Anliker - Clinical Chemistry and …, 2023 - degruyter.com
The immune response is accompanied by the activation of a highly complex network of
immune activator and inhibitor pathways. Immune defense reactions coexist with reactions …
immune activator and inhibitor pathways. Immune defense reactions coexist with reactions …
A new blood group antigen is defined by anti‐CD 59, detected in a CD 59‐deficient patient
M Anliker, I von Zabern, B Höchsmann, H Kyrieleis… - …, 2014 - Wiley Online Library
Background CD 59 is a cell surface glycoprotein of approximately 20 kDa limiting the lytic
activity of the terminal complement complex C 5b‐9. Although CD 59 is known as a red blood …
activity of the terminal complement complex C 5b‐9. Although CD 59 is known as a red blood …
Selectivity of C3-opsonin targeted complement inhibitors: a distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients
…, MJ Harder, EM Nichols, M Hebecker, M Anliker… - Immunobiology, 2016 - Elsevier
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated cell
lysis due to deficiency of GPI-anchored complement regulators. Blockage of the lytic …
lysis due to deficiency of GPI-anchored complement regulators. Blockage of the lytic …
